Candel Therapeutics, Inc. Common Stock (CADL)
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Candel Therapeutics, Inc. Common Stock (CADL) is listed on Nasdaq, where it has traded since July 27, 2021.
- Listed On
- Nasdaq
- Listed Since
- July 27, 2021
- Employees
- 55
- Market Cap
- $843M
About Candel Therapeutics, Inc. Common Stock
Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 133 institutions reported holding CADL, with 50.4 million shares worth $518.8 million in aggregate. The largest reported holder was FMR, with 11.0 million shares worth $113.2 million. Of the 5 largest holders listed below, 4 added shares and 1 held its position unchanged during the quarter.
| Institution | Shares | Value | Quarter change |
|---|---|---|---|
| FMR | 10,990,535 | $113M | Added 0.03% |
| Rtw Investments | 6,422,018 | $66M | Unchanged |
| BlackRock | 4,969,040 | $51M | Added 59.83% |
| Vanguard | 3,579,513 | $37M | Added 18.36% |
| State Street | 3,549,823 | $37M | Added 333.67% |
Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.
Frequently asked questions
What is CADL?
Candel Therapeutics, Inc. Common Stock (CADL) is listed on Nasdaq, where it has traded since July 27, 2021.
Who are the largest institutional holders of CADL?
In 13F filings for the quarter ended June 30, 2026, the largest reported holders of CADL were FMR, Rtw Investments and BlackRock.
How many institutions own CADL?
133 institutions reported a position in CADL for the quarter ended June 30, 2026, worth $518.8 million in total.
Did institutions buy or sell CADL last quarter?
Of the 5 largest reported holders, 4 added shares and 1 held its position unchanged during the quarter. Every reported holder and its change is on the SentiSense ownership page for CADL.
Every reported institutional holder, plus insider and congressional trades in CADL, on SentiSense.